A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...

Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven biotechnology company has ...

Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC. Click here to find out why I ...

On January 6, the U.S. Food and Drug Administration (“FDA” or the “Agency”) released a draft guidance titled “Accelerated Approval and ...

Credit: Getty Images The FDA is expected to decide on treatments ... as assessed by the proportion of patients with at least a 20% reduction in target tumor volume on consecutive scans during ...

California is not one of those states. Newsom in October rejected a $35 monthly insulin copay cap. In his veto message, he cited the state’s $100 million investment in insulin production as an example ...

Study to be conducted under $3.6 million NIH grant DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), ...

Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...

Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with ...

The FDA last year also approved several drugs designed to ... Merck's Winrevair became the first drug to target the root cause of pulmonary arterial hypertension, a progressive and life ...